Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference.
OBJECTIVE
To evaluate the potential association between sexual motivation and patterns of erectile dysfunction (ED) therapy among a large cohort of localized prostate cancer treatment survivors.


METHODS
The use of medications and devices to improve erections and sexual health-related quality of life (HRQOL) were evaluated using a mailed Expanded Prostate Cancer Index Composite survey administered to 896 men 4 to 8 years after brachytherapy, three-dimensional conformal external beam radiotherapy (3D-CRT), or radical prostatectomy and 112 control men. The responding participants (73% of those surveyed) were classified by prostate cancer treatment, sexual motivation, and ED therapy use. Bivariate and multivariate analyses were used to identify the factors associated with ED therapy use and sexual HRQOL outcome.


RESULTS
The quality of erections unassisted by medications or devices was not different among the treatment groups. Prostate cancer survivors used medications or devices for ED more commonly than did the control men (30% versus 13%; P <0.01). One half of the prostate cancer survivors with ED reported indifference regarding their ED (small to no sexual bother despite absent or poor unassisted erections). Conversely, among men who were bothered by poor erections, 48% of the brachytherapy, 61% of the 3D-CRT, and 23% of radical prostatectomy subjects had never tried commonly available medications or devices to improve their erections (P <0.01). The current use of at least one erection aid was an independent determinant of more favorable sexual HRQOL (P <0.01).


CONCLUSIONS
Many men who are bothered by posttreatment ED reported never having tried medications or devices to improve their erections. The lack of ED therapy was more prevalent among patients with erectile concerns after brachytherapy or 3D-CRT than after radical prostatectomy, suggesting possible opportunities for improving sexual HRQOL among long-term survivors.
Miller
David C
DC
Michigan Urology Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA. msanda@bidmc.harvard.edu
Wei
John T
JT
Dunn
Rodney L
RL
Montie
James E
JE
Pimentel
Hector
H
Sandler
Howard M
HM
McLaughlin
P William
PW
Sanda
Martin G
MG
D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects; D003430:Cross-Sectional Studies; D007172:Erectile Dysfunction / Q000209:etiology / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D006801:Humans; D008297:Male; D009042:Motivation; D010410:Penile Erection; D011468:Prostatectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000628:therapy*; D011788:Quality of Life; D012725:Sexual Behavior